Justin Choi

Justin Choi

Auto-generated profile, based on publicly available information

Justin Choi

Memorial Sloan Kettering Cancer Center, New York, New York, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2024 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
CZCarolyn W. Zhu
Carolyn W. Zhu
JCJustin Choi
Justin Choi
WHWilliam Hung
William Hung
MSMary Sano
Mary Sano

1 February 2025 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
ESEthan Shin
Ethan Shin
JCJustin Choi
Justin Choi
THTony K.W. Hung
Tony K.W. Hung
CPChester Poon
Chester Poon
NRNadeem Riaz
Nadeem Riaz
JKJung Julie Kang
Jung Julie Kang
PURPOSE: Treatment deintensification for human papillomavirus–positive (HPV+)-associated oropharyngeal cancer (OPC) has been the catalyst of experts worldwide. In situ hybridization is optimal to identify HPV+ OPC, but immunohistochemistry for its surrogate p16INK4a (p16) is standard-of-care given its availability and sensitivity. HPV testing is not required for clinical management, so treatments are often administered on the basis of p16 status alone. However, the prognosis of p16/HPV discordant tumors is uncertain. MATERIALS AND METHODS: This cohort study included 727 consecutive patients with OPC with digitized unstructured pathology reports receiving curative radiation therapy at an academic cancer center. Natural language processing (NLP) methods were used to classify biomarker status and compared against manually derived classification. Patients were excluded if either p16 or HPV testing was not performed or equivocal. Primary end points were progression-free survival (PFS), cancer-specific survival (CSS), and overall survival. RESULTS: NLP classified p16 and HPV status from a majority (91%) of reports. Accuracy, positive predictive value, sensitivity, and F -score for NLP-derived p16/HPV were 84%/82%, 91%/87%, 90%/89%, and 90%/88%, respectively. Four groups were identified: p16-positive (p16+)/HPV+ (75%), p16+/HPV-negative (HPV–; 13%), p16-negative (p16–)/HPV– (10%), and p16–/HPV+ (2%). There was no statistically significant difference in outcomes between p16+/HPV– and p16–/HPV– patients (5-year PFS 76.1% v 68.9%; P = .12; 5-year CSS 81.5% v 84.9%; P = .22). Number needed to harm calculations estimated one excess cancer-related death for every 10 p16+/HPV– patients, compared with that expected with p16+/HPV+ patients. CONCLUSION: NLP classified head and neck cancer pathology reports with high concordance with gold-standard categorization, but a conspicuous portion of reports could not be interpreted. p16/HPV discordant OPC constitutes a noteworthy minority of patients. The inferior prognosis of p16+/HPV– suggests that p16 alone for prognostication is insufficient—especially when considering treatment de-escalation.

7 June 2025 in Journal of Radiation Research and Applied Sciences
Verified
Journal Article
Open access
JCJustin Choi
Justin Choi
FMFasil Mathews
Fasil Mathews
RRRichard Rosenfeld
Richard Rosenfeld
OAOfer Azoulay
Ofer Azoulay
KSKrishnamurthi Sundaram
Krishnamurthi Sundaram

1 June 2025
Verified
Journal Article
Closed access
JCJustin Choi
Justin Choi
ESEric Sherman
Eric Sherman
EDEdward Christopher Dee
Edward Christopher Dee
TTTeeradon Treechairusame
Teeradon Treechairusame
KZKaveh Zakeri
Kaveh Zakeri
Nancy LeeNancy Lee
Nancy Lee

8 October 2026 in Thyroid®
Verified
Journal Article
Closed access
JCJustin Choi
Justin Choi
SWShuai Wang
Shuai Wang
ESEric J. Sherman
Eric J. Sherman
EDEdward Christopher Dee
Edward Christopher Dee
ZZZhigang Zhang
Zhigang Zhang
NLNancy Y. Lee
Nancy Y. Lee
Background: External beam radiotherapy (RT) is indicated for high-risk, gross residual, unresected, or recurrent differentiated thyroid cancer (DTC) when further surgery is not recommended. Although RT improves time to locoregional control (LRC), head and neck toxicities remain a significant concern. Whether field reduction can lessen toxicity while maintaining tumor control in advanced DTC remains undefined. Methods: In this retrospective cohort study, detailed RT plans were available for 284 of 327 consecutive nonanaplastic, nonmedullary DTC patients treated from 1999 to 2023 at a single tertiary center. Treatment fields were classified as: comprehensive (bilateral central compartment and bilateral necks), ipsilateral (central compartment plus ipsilateral neck), or central (central compartment only). Acute toxicities were defined as the worst grade within 90 days of RT start (CTCAE) and late toxicities thereafter (RTOG). Time to locoregional recurrence (LRR) was assessed using cumulative incidence functions, treating death without LRR as a competing risk. Overall median follow-up was 8.9 years (interquartile range 5.3–12.7 years). Results: Among 284 patients, 103 (36%) received comprehensive, 116 (41%) ipsilateral, and 65 (23%) central fields. Group differences in acute grade ≥ 2 toxicities were observed in xerostomia (36% comprehensive, 17% ipsilateral, 16% central, p = 0.002), dysphagia (58% comprehensive, 48% ipsilateral, 36% central, p = 0.02), voice changes (39% comprehensive, 22% ipsilateral, 28% central, p = 0.02) and fatigue (41% comprehensive, 28% ipsilateral, 22% central, p = 0.02). Also differing was late grade ≥ 2 dysphagia (23% comprehensive, 6% ipsilateral, 8% central, p = 0.0004). Percutaneous endoscopic gastrostomy tube placement was higher in comprehensive versus central ( p = 0.0003) and ipsilateral ( p = 0.019) fields. In-field failure rates were 11/103 (10.7%) for comprehensive, 11/116 (9.5%) for ipsilateral, and 5/65 (7.7%) for central fields, with no difference in LRC across groups ( p = 0.88). Six patients with central RT developed out-of-field lateral neck recurrences, all successfully salvaged with surgery. Conclusions: Progressive RT field reduction in appropriately selected DTC patients was associated with significantly lower rates of acute and late toxicities without compromising LRC. These findings support individualized field selection and highlight the potential role of RT field de-escalation in this population. Prospective multicenter studies are needed to confirm these findings.